Filing Details
- Accession Number:
- 0000919574-25-002726
- Form Type:
- 13G Filing
- Publication Date:
- 2025-05-01 20:00:00
- Filed By:
- ABG WTT-Ceribell Limited
- Company:
- Ceribell Inc.
- Filing Date:
- 2025-05-02
- SEC Url:
- 13G Filing
Ownership Summary
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
Name | Beneficially Owned Number of Shares | Beneficially Owned Number of Aggregate Shares | Percent of Class |
---|---|---|---|
ABG WTT-Ceribell Limited | 0 | 2,441,267 | 6.8% |
ABG V-Ceribell Limited | 0 | 2,441,267 | 6.8% |
Ally Bridge Group Global Life Science Capital Partners V, L.P. | 0 | 2,441,267 | 6.8% |
ABG Global Life Science Capital Partners V GP, L.P. | 0 | 2,441,267 | 6.8% |
ABG Global Life Science Capital Partners V GP Limited | 0 | 2,441,267 | 6.8% |
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. | 0 | 2,441,267 | 6.8% |
ABG-WTT Global Life Science Capital Partners GP, L.P. | 0 | 2,441,267 | 6.8% |
ABG-WTT Global Life Science Capital Partners GP Limited | 0 | 2,441,267 | 6.8% |
ABG Management Ltd. | 0 | 2,441,267 | 6.8% |
Ally Bridge Group (PE) LLC | 0 | 2,441,267 | 6.8% |
Fan Yu | 0 | 2,441,267 | 6.8% |
Filing
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13G
|
UNDER THE SECURITIES EXCHANGE ACT OF 1934
|
Ceribell, Inc. (Name of Issuer) |
Common Stock, $0.001 par value per share (Title of Class of Securities) |
15678C102 (CUSIP Number) |
12/31/2024 (Date of Event Which Requires Filing of this Statement) |
Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
![]() |
![]() |
![]() |
SCHEDULE 13G
|
CUSIP No. | 15678C102 |
1 | Names of Reporting Persons
ABG WTT-Ceribell Limited | ||||||||
2 | Check the appropriate box if a member of a Group (see instructions)
![]() ![]() | ||||||||
3 | Sec Use Only | ||||||||
4 | Citizenship or Place of Organization
CAYMAN ISLANDS
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
2,441,267.00 | ||||||||
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
![]() | ||||||||
11 | Percent of class represented by amount in row (9)
6.8 % | ||||||||
12 | Type of Reporting Person (See Instructions)
CO |
Comment for Type of Reporting Person: The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.
SCHEDULE 13G
|
CUSIP No. | 15678C102 |
1 | Names of Reporting Persons
ABG V-Ceribell Limited | ||||||||
2 | Check the appropriate box if a member of a Group (see instructions)
![]() ![]() | ||||||||
3 | Sec Use Only | ||||||||
4 | Citizenship or Place of Organization
CAYMAN ISLANDS
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
2,441,267.00 | ||||||||
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
![]() | ||||||||
11 | Percent of class represented by amount in row (9)
6.8 % | ||||||||
12 | Type of Reporting Person (See Instructions)
CO |
Comment for Type of Reporting Person: ABG V-Ceribell Limited is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited.
The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.
SCHEDULE 13G
|
CUSIP No. | 15678C102 |
1 | Names of Reporting Persons
Ally Bridge Group Global Life Science Capital Partners V, L.P. | ||||||||
2 | Check the appropriate box if a member of a Group (see instructions)
![]() ![]() | ||||||||
3 | Sec Use Only | ||||||||
4 | Citizenship or Place of Organization
CAYMAN ISLANDS
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
2,441,267.00 | ||||||||
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
![]() | ||||||||
11 | Percent of class represented by amount in row (9)
6.8 % | ||||||||
12 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person: Ally Bridge Group Global Life Science Capital Partners V, L.P. is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited.
The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.
SCHEDULE 13G
|
CUSIP No. | 15678C102 |
1 | Names of Reporting Persons
ABG Global Life Science Capital Partners V GP, L.P. | ||||||||
2 | Check the appropriate box if a member of a Group (see instructions)
![]() ![]() | ||||||||
3 | Sec Use Only | ||||||||
4 | Citizenship or Place of Organization
CAYMAN ISLANDS
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
2,441,267.00 | ||||||||
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
![]() | ||||||||
11 | Percent of class represented by amount in row (9)
6.8 % | ||||||||
12 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person: ABG Global Life Science Capital Partners V GP, L.P. is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited.
The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.
SCHEDULE 13G
|
CUSIP No. | 15678C102 |
1 | Names of Reporting Persons
ABG Global Life Science Capital Partners V GP Limited | ||||||||
2 | Check the appropriate box if a member of a Group (see instructions)
![]() ![]() | ||||||||
3 | Sec Use Only | ||||||||
4 | Citizenship or Place of Organization
CAYMAN ISLANDS
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
2,441,267.00 | ||||||||
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
![]() | ||||||||
11 | Percent of class represented by amount in row (9)
6.8 % | ||||||||
12 | Type of Reporting Person (See Instructions)
CO |
Comment for Type of Reporting Person: ABG Global Life Science Capital Partners V GP Limited is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited.
The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.
SCHEDULE 13G
|
CUSIP No. | 15678C102 |
1 | Names of Reporting Persons
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. | ||||||||
2 | Check the appropriate box if a member of a Group (see instructions)
![]() ![]() | ||||||||
3 | Sec Use Only | ||||||||
4 | Citizenship or Place of Organization
CAYMAN ISLANDS
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
2,441,267.00 | ||||||||
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
![]() | ||||||||
11 | Percent of class represented by amount in row (9)
6.8 % | ||||||||
12 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person: Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited.
The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.
SCHEDULE 13G
|
CUSIP No. | 15678C102 |
1 | Names of Reporting Persons
ABG-WTT Global Life Science Capital Partners GP, L.P. | ||||||||
2 | Check the appropriate box if a member of a Group (see instructions)
![]() ![]() | ||||||||
3 | Sec Use Only | ||||||||
4 | Citizenship or Place of Organization
CAYMAN ISLANDS
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
2,441,267.00 | ||||||||
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
![]() | ||||||||
11 | Percent of class represented by amount in row (9)
6.8 % | ||||||||
12 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person: ABG-WTT Global Life Science Capital Partners GP, L.P. is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited.
The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.
SCHEDULE 13G
|
CUSIP No. | 15678C102 |
1 | Names of Reporting Persons
ABG-WTT Global Life Science Capital Partners GP Limited | ||||||||
2 | Check the appropriate box if a member of a Group (see instructions)
![]() ![]() | ||||||||
3 | Sec Use Only | ||||||||
4 | Citizenship or Place of Organization
CAYMAN ISLANDS
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
2,441,267.00 | ||||||||
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
![]() | ||||||||
11 | Percent of class represented by amount in row (9)
6.8 % | ||||||||
12 | Type of Reporting Person (See Instructions)
CO |
Comment for Type of Reporting Person: ABG-WTT Global Life Science Capital Partners GP Limited is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited.
The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.
SCHEDULE 13G
|
CUSIP No. | 15678C102 |
1 | Names of Reporting Persons
ABG Management Ltd. | ||||||||
2 | Check the appropriate box if a member of a Group (see instructions)
![]() ![]() | ||||||||
3 | Sec Use Only | ||||||||
4 | Citizenship or Place of Organization
CAYMAN ISLANDS
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
2,441,267.00 | ||||||||
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
![]() | ||||||||
11 | Percent of class represented by amount in row (9)
6.8 % | ||||||||
12 | Type of Reporting Person (See Instructions)
CO |
Comment for Type of Reporting Person: ABG Management Ltd. is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited.
The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.
SCHEDULE 13G
|
CUSIP No. | 15678C102 |
1 | Names of Reporting Persons
Ally Bridge Group (PE) LLC | ||||||||
2 | Check the appropriate box if a member of a Group (see instructions)
![]() ![]() | ||||||||
3 | Sec Use Only | ||||||||
4 | Citizenship or Place of Organization
DELAWARE
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
2,441,267.00 | ||||||||
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
![]() | ||||||||
11 | Percent of class represented by amount in row (9)
6.8 % | ||||||||
12 | Type of Reporting Person (See Instructions)
IA, OO |
Comment for Type of Reporting Person: Ally Bridge Group (PE) LLC is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited.
The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.
SCHEDULE 13G
|
CUSIP No. | 15678C102 |
1 | Names of Reporting Persons
Fan Yu | ||||||||
2 | Check the appropriate box if a member of a Group (see instructions)
![]() ![]() | ||||||||
3 | Sec Use Only | ||||||||
4 | Citizenship or Place of Organization
MALTA
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
2,441,267.00 | ||||||||
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
![]() | ||||||||
11 | Percent of class represented by amount in row (9)
6.8 % | ||||||||
12 | Type of Reporting Person (See Instructions)
IN |
Comment for Type of Reporting Person: Fan Yu is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited.
The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.
SCHEDULE 13G
|
Item 1. | ||
(a) | Name of issuer:
Ceribell, Inc. | |
(b) | Address of issuer's principal executive offices:
360 N. Pastoria Avenue, Sunnyvale, California 94085 | |
Item 2. | ||
(a) | Name of person filing:
This Schedule 13G is jointly filed, pursuant to a Joint Filing Agreement attached hereto as Exhibit 1
ABG WTT-Ceribell Limited
ABG V-Ceribell Limited
Ally Bridge Group Global Life Science Capital Partners V, L.P.
ABG Global Life Science Capital Partners V GP, L.P.
ABG Global Life Science Capital Partners V GP Limited
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P.
ABG-WTT Global Life Science Capital Partners GP, L.P.
ABG-WTT Global Life Science Capital Partners GP Limited
ABG Management Ltd.
Ally Bridge Group (PE) LLC
Fan Yu | |
(b) | Address or principal business office or, if none, residence:
ABG WTT-Ceribell Limited
c/o Maples Corporate Services Limited
Ugland House, Grand Cayman
Cayman Islands
KY1-1104
ABG V-Ceribell Limited
c/o Maples Corporate Services Limited
Ugland House, Grand Cayman
Cayman Islands
KY1-1104
Ally Bridge Group Global Life Science Capital Partners V, L.P
c/o Maples Corporate Services Limited
Ugland House, Grand Cayman
Cayman Islands
KY1-1104
ABG Global Life Science Capital Partners V GP, L.P.
c/o Maples Corporate Services Limited
Ugland House, Grand Cayman
Cayman Islands
KY1-1104
ABG Global Life Science Capital Partners V GP Limited
c/o Maples Corporate Services Limited
Ugland House, Grand Cayman
Cayman Islands
KY1-1104
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P.
c/o Maples Corporate Services Limited
Ugland House, Grand Cayman
Cayman Islands
KY1-1104
ABG-WTT Global Life Science Capital Partners GP, L.P.
c/o Maples Corporate Services Limited
Ugland House, Grand Cayman
Cayman Islands
KY1-1104
ABG-WTT Global Life Science Capital Partners GP Limited
c/o Maples Corporate Services Limited
Ugland House, Grand Cayman
Cayman Islands
KY1-1104
ABG Management Ltd.
c/o Maples Corporate Services Limited
Ugland House, Grand Cayman
Cayman Islands
KY1-1104
Ally Bridge Group (PE) LLC
430 Park Avenue
New York, New York 10022
United States of America
Fan Yu
c/o Maples Corporate Services Limited
Ugland House, Grand Cayman
Cayman Islands
KY1-1104 | |
(c) | Citizenship:
ABG WTT-Ceribell Limited - Cayman Islands
ABG V-Ceribell Limited - Cayman Islands
Ally Bridge Group Global Life Science Capital Partners V, L.P. - Cayman Islands
ABG Global Life Science Capital Partners V GP, L.P. - Cayman Islands
ABG Global Life Science Capital Partners V GP Limited - Cayman Islands
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. - Cayman Islands
ABG-WTT Global Life Science Capital Partners GP, L.P. - Cayman Islands
ABG-WTT Global Life Science Capital Partners GP Limited - Cayman Islands
ABG Management Ltd.- Cayman Islands
Ally Bridge Group (PE) LLC - Delaware
Fan Yu - Malta | |
(d) | Title of class of securities:
Common Stock, $0.001 par value per share | |
(e) | CUSIP No.:
15678C102 | |
Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: | |
(a) | ![]() | |
(b) | ![]() | |
(c) | ![]() | |
(d) | ![]() | |
(e) | ![]() | |
(f) | ![]() | |
(g) | ![]() | |
(h) | ![]() | |
(i) | ![]() | |
(j) | ![]() please specify the type of institution: | |
(k) | ![]() | |
Item 4. | Ownership | |
(a) | Amount beneficially owned:
ABG WTT-Ceribell Limited: 2,441,267
ABG V-Ceribell Limited: 2,441,267
Ally Bridge Group Global Life Science Capital Partners V, L.P.: 2,441,267
ABG Global Life Science Capital Partners V GP, L.P.: 2,441,267
ABG Global Life Science Capital Partners V GP Limited: 2,441,267
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P.: 2,441,267
ABG-WTT Global Life Science Capital Partners GP, L.P.: 2,441,267
ABG-WTT Global Life Science Capital Partners GP Limited: 2,441,267
ABG Management Ltd.: 2,441,267
Ally Bridge Group (PE) LLC: 2,441,267
Fan Yu: 2,441,267 | |
(b) | Percent of class:
ABG WTT-Ceribell Limited: 6.8%
ABG V-Ceribell Limited: 6.8%
Ally Bridge Group Global Life Science Capital Partners V, L.P. : 6.8%
ABG Global Life Science Capital Partners V GP, L.P. : 6.8%
ABG Global Life Science Capital Partners V GP Limited: 6.8%
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. : 6.8%
ABG-WTT Global Life Science Capital Partners GP, L.P.: 6.8%
ABG-WTT Global Life Science Capital Partners GP Limited: 6.8%
ABG Management Ltd.: 6.8%
Ally Bridge Group (PE) LLC: 6.8%
Fan Yu: 6.8% | |
(c) | Number of shares as to which the person has:
| |
(i) Sole power to vote or to direct the vote:
ABG WTT-Ceribell Limited: 0
ABG V-Ceribell Limited: 0
Ally Bridge Group Global Life Science Capital Partners V, L.P. : 0
ABG Global Life Science Capital Partners V GP, L.P. : 0
ABG Global Life Science Capital Partners V GP Limited: 0
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. : 0
ABG-WTT Global Life Science Capital Partners GP, L.P.: 0
ABG-WTT Global Life Science Capital Partners GP Limited: 0
ABG Management Ltd.: 0
Ally Bridge Group (PE) LLC: 0
Fan Yu: 0 | ||
(ii) Shared power to vote or to direct the vote:
ABG WTT-Ceribell Limited: 2,441,267
ABG V-Ceribell Limited: 2,441,267
Ally Bridge Group Global Life Science Capital Partners V, L.P.: 2,441,267
ABG Global Life Science Capital Partners V GP, L.P.: 2,441,267
ABG Global Life Science Capital Partners V GP Limited: 2,441,267
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. : 2,441,267
ABG-WTT Global Life Science Capital Partners GP, L.P.: 2,441,267
ABG-WTT Global Life Science Capital Partners GP Limited: 2,441,267
ABG Management Ltd.: 2,441,267
Ally Bridge Group (PE) LLC: 2,441,267
Fan Yu: 2,441,267 | ||
(iii) Sole power to dispose or to direct the disposition of:
ABG WTT-Ceribell Limited: 0
ABG V-Ceribell Limited: 0
Ally Bridge Group Global Life Science Capital Partners V, L.P. : 0
ABG Global Life Science Capital Partners V GP, L.P. : 0
ABG Global Life Science Capital Partners V GP Limited: 0
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. : 0
ABG-WTT Global Life Science Capital Partners GP, L.P.: 0
ABG-WTT Global Life Science Capital Partners GP Limited: 0
ABG Management Ltd.: 0
Ally Bridge Group (PE) LLC: 0
Fan Yu: 0 | ||
(iv) Shared power to dispose or to direct the disposition of:
ABG WTT-Ceribell Limited: 2,441,267
ABG V-Ceribell Limited: 2,441,267
Ally Bridge Group Global Life Science Capital Partners V, L.P.: 2,441,267
ABG Global Life Science Capital Partners V GP, L.P.: 2,441,267
ABG Global Life Science Capital Partners V GP Limited: 2,441,267
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. : 2,441,267
ABG-WTT Global Life Science Capital Partners GP, L.P.: 2,441,267
ABG-WTT Global Life Science Capital Partners GP Limited: 2,441,267
ABG Management Ltd.: 2,441,267
Ally Bridge Group (PE) LLC: 2,441,267
Fan Yu: 2,441,267 | ||
Item 5. | Ownership of 5 Percent or Less of a Class. | |
Item 6. | Ownership of more than 5 Percent on Behalf of Another Person. | |
Not Applicable
| ||
Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. | |
Not Applicable
| ||
Item 8. | Identification and Classification of Members of the Group. | |
Not Applicable
| ||
Item 9. | Notice of Dissolution of Group. | |
Not Applicable
|
Item 10. | Certifications: |
Not Applicable
|
SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exhibit Information
|
[Exhibit A - Joint Filing Agreement] |